7-methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine structure
|
Common Name | 7-methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine | ||
|---|---|---|---|---|
| CAS Number | 84201-40-1 | Molecular Weight | 224.34600 | |
| Density | 1.25g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C10H12N2S2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine |
|---|---|
| Synonym | More Synonyms |
| Density | 1.25g/cm3 |
|---|---|
| Molecular Formula | C10H12N2S2 |
| Molecular Weight | 224.34600 |
| Exact Mass | 224.04400 |
| PSA | 67.90000 |
| LogP | 3.08650 |
| Index of Refraction | 1.656 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
|
~76%
7-methyl-6,8-bi... CAS#:84201-40-1 |
| Literature: Largeron, M.; Fleury, D.; Fleury, M. B. Tetrahedron, 1986 , vol. 42, # 1 p. 409 - 416 |
|
~41%
7-methyl-6,8-bi... CAS#:84201-40-1 |
| Literature: Largeron, M.; Fleury, D.; Fleury, M. B. Tetrahedron, 1986 , vol. 42, # 1 p. 409 - 416 |
|
~%
7-methyl-6,8-bi... CAS#:84201-40-1 |
| Literature: Corbet, J. P.; Paris, J. M.; Cotrel, C. Tetrahedron Letters, 1982 , vol. 23, # 35 p. 3565 - 3566 |
|
~%
7-methyl-6,8-bi... CAS#:84201-40-1
Detail
|
| Literature: Largeron, M.; Martens, T.; Fleury, M. B. Tetrahedron, 1987 , vol. 43, # 15 p. 3421 - 3428 |
|
~20%
7-methyl-6,8-bi... CAS#:84201-40-1 |
| Literature: Largeron, M.; Fleury, D.; Fleury, M. B. Tetrahedron, 1986 , vol. 42, # 1 p. 409 - 416 |
|
~%
7-methyl-6,8-bi... CAS#:84201-40-1
Detail
|
| Literature: Largeron, M.; Martens, T.; Fleury, M. B. Tetrahedron, 1987 , vol. 43, # 15 p. 3421 - 3428 |
|
~%
7-methyl-6,8-bi... CAS#:84201-40-1 |
| Literature: Fleury, M. B.; Largeron, M.; Barreau, M.; Vuilhorgne, M. Tetrahedron, 1985 , vol. 41, # 18 p. 3705 - 3715 |
|
Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
Clin. Pharmacol. Ther. 88(3) , 360-8, (2010) Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylt... |
|
|
Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.
Mol. Pharmacol. 48(1) , 15-20, (1995) Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication in vitro (ED50 approximately 10 microM), undergoes extensive metabolism in vivo. Most of the orally administered drug undergoe... |
| 7-methyl-6,8-dimethylthio-pyrrolo<1,2-a>pyrazine |
| MIII |
| Mbmtpp |
| 6,8-dimethylthio-7-methylpyrrolo <1,2-a> pyrazine |
| Metabolite III |